Castleman Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CST005 MIFTS: 56	Castleman Disease Categories: Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Castleman Disease

MalaCards integrated aliases for Castleman Disease:

Name: Castleman Disease ¹² ²⁰ ³⁶ ⁵⁴ ⁴⁴ ¹⁵

Angiofollicular Ganglionic Hyperplasia ²⁰ ⁴⁴ ⁷⁰

Giant Lymph Node Hyperplasia ¹² ²⁰ ¹⁷

Angiofollicular Lymph Hyperplasia ¹² ²⁰

Castleman's Disease ⁷³ ¹⁵

Angiofollicular Lymph Node Hyperplasia ¹²

Angiolymphoid Hyperplasia ⁷⁰

Benign Giant Lymphoma ²⁰

Lymphoid Hamartoma ¹²

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0111157

KEGG ³⁶ H01479

MeSH ⁴⁴ C536362 D005871

NCIt ⁵⁰ C3056

SNOMED-CT ⁶⁷ 207036003

ICD10 ³² D47.Z2

EFO ¹⁷ EFO_1001332

UMLS ⁷⁰ C0017531 C2931179

Sources

Summaries for Castleman Disease

KEGG : ³⁶ Castleman disease is a rare lymphoproliferative disorder with two primary subtypes that vary in presentation and course. Unicentric Castleman disease is localized and carries an excellent prognosis. Multicentric Castleman disease can be associated with HIV and human herpesvirus-8 and is characterized by generalized lymphadenopathy and systemic symptoms, such as fever, fatigue, anorexia, anemia, and cachexia. Castleman disease is unique in that dysregulated secretion of interleukin-6 (IL-6) plays a central pathogenetic role, although the exact events precipitating the oversecretion of IL-6 are unknown. Recently, two antibody-based therapeutics targeting components of the IL-6/IL-6R complex have been approved for the treatment of Castleman disease. Tocilizumab is a monoclonal antibody directed against the IL-6 receptor, and siltuximab is a monoclonal antibody specific for IL-6.

MalaCards based summary : Castleman Disease, also known as angiofollicular ganglionic hyperplasia, is related to human herpesvirus 8 and multicentric castleman disease. An important gene associated with Castleman Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and JAK-STAT signaling pathway. The drugs Siltuximab and Zanubrutinib have been mentioned in the context of this disorder. Affiliated tissues include lymph node, bone and bone marrow, and related phenotypes are fatigue and anemia

Disease Ontology : ¹² A lymphoproliferative syndrome characterized by one or more enlarged lymph nodes containing cells with hyaline-vascular, plasmacytic, or mixed appearance microscopically.

GARD : ²⁰ Castleman disease (CD) is a rare condition that affects the lymph nodes and related tissues. There are two main forms: unicentric CD and multicentric CD. Unicentric CD is a "localized" condition that is generally confined to a single set of lymph nodes, while multicentric CD is a "systemic" disease that affects multiple sets of lymph nodes and other tissues throughout the body. The exact underlying cause of CD is currently unknown; however, it is thought to occur sporadically in people with no family history of the condition. Treatment varies based on the form of the condition, the severity of symptoms and whether or not the affected person also has an HIV and/or human herpes virus type 8 (HHV-8) infection. For more specific information about each form of CD, please visit GARD's unicentric Castleman disease and multicentric Castleman disease pages.

Wikipedia : ⁷³ Castleman disease is a group of uncommon lymphoproliferative disorders characterized by lymph node... more...

Sources

Related Diseases for Castleman Disease

Diseases related to Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 807)

#	Related Disease	Score	Top Affiliating Genes
1	human herpesvirus 8	32.5	IL6ST IL6R IL6
2	multicentric castleman disease	32.2	SDC1 MTOR KRT15 IL6 IL10 IFNG
3	polyclonal hypergammaglobulinemia	31.2	IL6 CXCL13 CRP
4	bronchiolitis obliterans	31.0	IL6 IL10 IFNG CRP
5	hemolytic anemia	30.9	IL10 IFNG CXCL13 CR1 CCL4
6	bronchiolitis	30.9	IL6 IL10 IFNG CRP CCL4
7	ulcerative colitis	30.8	IL6 IL10 IFNG CRP
8	infective endocarditis	30.7	IL6 CRP CCL4
9	exanthem	30.7	MTOR IL6 IL10 IFNG H2AC18 CRP
10	temporal arteritis	30.7	IL6 IFNG CRP
11	proliferative glomerulonephritis	30.7	IL6 IFNG CR1
12	adult-onset still's disease	30.7	IL6 IFNG CRP
13	peritonitis	30.7	IL6 IL10 CRP CR1
14	plasmacytoma	30.7	IL6ST IL6R IL6
15	pneumonia	30.7	IL6 IL10 IFNG CRP
16	stomatitis	30.6	MTOR IL6 IL10 IFNG
17	intestinal obstruction	30.6	MTOR IL6 CRP
18	follicular dendritic cell sarcoma	30.6	FCER2 DSG3 CXCL13 CR2 CR1
19	lichen planus	30.6	IL6 IL10 IFNG DSG3
20	rare tumor	30.6	FSCN1 FCER2 CR2
21	polyradiculoneuropathy	30.5	IL10 IFNG CCL4
22	pancytopenia	30.5	IL6 IFNG H2AC18 CRP
23	aphthous stomatitis	30.5	IL6 IL10 IFNG
24	brucellosis	30.5	IL6 IL10 IFNG CRP
25	crohn's disease	30.5	IL6 IL10 IFNG CRP
26	lymphoid interstitial pneumonia	30.5	IL6 H2AC18 CRP
27	thyroiditis	30.5	IL6 IL10 IFNG CRP
28	lymphadenitis	30.5	IL10 IFNG CRP
29	liver cirrhosis	30.5	IL6 IL10 IFNG CRP CR1
30	interstitial lung disease	30.5	IL6 IL10 IFNG CRP
31	uveitis	30.5	IL6 IL10 IFNG CCL4
32	human immunodeficiency virus type 1	30.4	IL10 IFNG CR2 CR1 CCL4
33	retinal detachment	30.4	IL6 IL10 IFNG CCL4
34	follicular lymphoma	30.4	MIR210 FCER2 CR2 CR1
35	rheumatoid arthritis	30.4	IL6ST IL6R IL6 IL10 IFNG CRP
36	celiac disease 1	30.4	IL6 IL10 IFNG H2AC18 CRP
37	syphilis	30.4	IL6 IFNG CRP
38	systemic autoimmune disease	30.4	IL6 CRP
39	lung abscess	30.4	IL6 IFNG CRP
40	bronchopneumonia	30.4	IL6 IL10 CRP
41	brain edema	30.4	IL6 IFNG CRP
42	allergic disease	30.4	IL6 IL10 IFNG FCER2
43	b-cell growth factor	30.4	IL6 IFNG
44	conjunctivitis	30.4	IL6 IL10 IFNG
45	bacterial sepsis	30.3	IL6 IL10 CRP
46	acute pyelonephritis	30.3	IL6 IL10 CRP
47	radiculopathy	30.3	IL6 IL10 CCL4
48	mixed connective tissue disease	30.3	IL6 IL10 IFNG
49	pericarditis	30.3	IL6 IFNG CRP
50	chronic inflammatory demyelinating polyradiculoneuropathy	30.3	IL10 IFNG CCL4

Graphical network of the top 20 diseases related to Castleman Disease:

Sources

Symptoms & Phenotypes for Castleman Disease

Human phenotypes related to Castleman Disease:

³¹ (show all 26)

#	Description	HPO Frequency	HPO Source Accession
1	fatigue ³¹	frequent (33%)	HP:0012378
2	anemia ³¹	frequent (33%)	HP:0001903
3	abdominal pain ³¹	frequent (33%)	HP:0002027
4	weight loss ³¹	frequent (33%)	HP:0001824
5	mediastinal lymphadenopathy ³¹	frequent (33%)	HP:0100721
6	elevated c-reactive protein level ³¹	frequent (33%)	HP:0011227
7	elevated erythrocyte sedimentation rate ³¹	frequent (33%)	HP:0003565
8	follicular hyperplasia ³¹	frequent (33%)	HP:0002729
9	increased circulating interleukin 6 ³¹	frequent (33%)	HP:0030783
10	nausea and vomiting ³¹	occasional (7.5%)	HP:0002017
11	jaundice ³¹	occasional (7.5%)	HP:0000952
12	cough ³¹	occasional (7.5%)	HP:0012735
13	abdominal distention ³¹	occasional (7.5%)	HP:0003270
14	generalized lymphadenopathy ³¹	occasional (7.5%)	HP:0008940
15	decreased mean corpuscular volume ³¹	occasional (7.5%)	HP:0025066
16	abdominal mass ³¹	occasional (7.5%)	HP:0031500
17	flank pain ³¹	occasional (7.5%)	HP:0030157
18	renal insufficiency ³¹	very rare (1%)	HP:0000083
19	thrombocytopenia ³¹	very rare (1%)	HP:0001873
20	hematuria ³¹	very rare (1%)	HP:0000790
21	dyspnea ³¹	very rare (1%)	HP:0002094
22	intestinal obstruction ³¹	very rare (1%)	HP:0005214
23	restrictive cardiomyopathy ³¹	very rare (1%)	HP:0001723
24	myelofibrosis ³¹	very rare (1%)	HP:0011974
25	ureteral obstruction ³¹	very rare (1%)	HP:0006000
26	anasarca ³¹	very rare (1%)	HP:0012050

MGI Mouse Phenotypes related to Castleman Disease:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.1	CXCL13 DSG3 FCER2 FSCN1 IFNG IL10
2	hematopoietic system	MP:0005397	9.97	CR2 CXCL13 DSG3 FCER2 FSCN1 IFNG
3	digestive/alimentary	MP:0005381	9.86	DSG3 FCER2 IFNG IL10 IL6 IL6ST
4	immune system	MP:0005387	9.8	CR2 CRP CXCL13 DSG3 FCER2 FSCN1
5	integument	MP:0010771	9.28	DSG3 FSCN1 IFNG IL10 IL6 IL6ST

Sources

Drugs & Therapeutics for Castleman Disease

Drugs for Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Siltuximab

Approved, Investigational

Phase 2

541502-14-1

Zanubrutinib

Approved, Investigational

Phase 2

1691249-45-2

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

5743

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

93860 387447

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

6436030 5284616

Zidovudine

Approved

Phase 2

30516-87-1

35370

Ganciclovir

Approved, Investigational

Phase 2

82410-32-0

3454

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Suramin

Investigational

Phase 2

145-63-1

5361

Analgesics

Phase 2

Histamine H1 Antagonists

Phase 2

Antipyretics

Phase 2

Histamine Antagonists

Phase 2

Pharmaceutical Solutions

Phase 2

Antiparasitic Agents

Phase 2

Antiprotozoal Agents

Phase 2

Anthelmintics

Phase 2

Protein Kinase Inhibitors

Phase 2

Antifungal Agents

Phase 2

Antimetabolites

Phase 2

Reverse Transcriptase Inhibitors

Phase 2

interferons

Phase 2

Interferon-alpha

Phase 2

Ganciclovir triphosphate

Phase 2

Antibodies

Phase 2

Immunoglobulins

Phase 2

Antibodies, Monoclonal

Phase 2

Methotrexate

Approved

Phase 1

1959-05-2, 59-05-2

126941

Levoleucovorin

Approved, Investigational

Phase 1

68538-85-2

149436

Daunorubicin

Approved

Phase 1

20830-81-3

30323

Cetuximab

Approved

Phase 1

205923-56-4

56842117 2333

Bevacizumab

Approved, Investigational

Phase 1

216974-75-3

Valproic acid

Approved, Investigational

Phase 1

99-66-1

3121

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 1

59-30-3

6037

Vitamin B9

Phase 1

Folic Acid Antagonists

Phase 1

Immunoglobulins, Intravenous

Phase 1

Keratolytic Agents

Phase 1

Dermatologic Agents

Phase 1

Vitamin B Complex

Phase 1

Folate

Phase 1

Podophyllotoxin

Phase 1

518-28-5

Neurotransmitter Agents

Phase 1

Psychotropic Drugs

Phase 1

Immunoglobulin G

Phase 1

Mitogens

Phase 1

Interventional clinical trials:

(show all 28)

#	Name	Status	NCT ID	Phase	Drugs
1	Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclovir	Withdrawn	NCT00361933	Phase 4	Valganciclovir
2	A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman's Disease	Completed	NCT01024036	Phase 2	Siltuximab;Placebo;Best Supportive Care (BSC)
3	An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease	Completed	NCT01400503	Phase 2	Siltuximab
4	Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease	Completed	NCT01441063	Phase 2	Zidovudine;Tocilizumab;Valganciclovir (VGC)
5	A PHASE II PILOT STUDY OF SURAMIN IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA AND PATIENTS WITH CASTLEMAN'S DISEASE	Completed	NCT00002652	Phase 2	suramin
6	The Efficacy and Safety of Zanuburutinib in Relapsed and Refractory Idiopathic Multicentric Castleman Disease (iMCD): a Prospective, Single-center, Single-arm Trial	Recruiting	NCT04743687	Phase 2	Zanubrutinib
7	Bortezomib, Cyclophosphamide and Dexamethasone (BCD) in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) : a Prospective, Single-center, Single-arm, Phase-II Pilot Trial	Recruiting	NCT03982771	Phase 2	Bortezomib;Cyclophosphamide;Dexamethason
8	A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease	Recruiting	NCT03933904	Phase 2	Sirolimus
9	Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity	Recruiting	NCT00092222	Phase 2	Etoposide;Interferon-alpha;Rituximab;Zidovudine;Liposomal Doxorubicin;Bortezomib;Valganciclovir;Doxorubicin;Vincristine;Cyclophosphamide;Filgrastim (G-CSF);Prednisone;Sirolimus
10	Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot Trial	Active, not recruiting	NCT03043105	Phase 2	Thalidomide, cyclophosphamide and prednisone
11	LCCC 1950 - Rituximab for Multicentric Castleman Disease in Malawi, A Single-Arm Phase II Safety/Efficacy Trial	Not yet recruiting	NCT04585893	Phase 2	Rituximab;Etoposide
12	Multicenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB)	Terminated	NCT00127569	Phase 2	Rituximab
13	Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease)	Withdrawn	NCT02228512	Phase 1, Phase 2	Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
14	A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma	Unknown status	NCT00891280	Phase 1	CX-4945 oral formulation
15	Provision of Tocilizumab for Patients With Multicentric Castleman's Disease Who Have Demonstrated Benefit From Previous Tocilizumab Treatment	Completed	NCT01183598	Phase 1	tocilizumab [RoActemra/Actemra]
16	A Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease	Completed	NCT00412321	Phase 1	CNTO 328
17	A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in Uganda	Recruiting	NCT03864419	Phase 1	Cyclophosphamide;Vincristine;Methotrexate;Doxorubicin;Doxorubicin Hydrochloride;Prednisone;Etoposide
18	A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications	Recruiting	NCT01552434	Phase 1	Temsirolimus;Valproic Acid
19	Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma	Terminated	NCT02109224	Phase 1	Ibrutinib
20	Unlock the Cell: Intracellular Inflammatory Pathways and Flow Cytometry Study for Castleman's Disease	Completed	NCT02853968
21	Epithelioid Hemangioma of Bone And Soft Tissue: a Benign Tumor With Metastatic Potential	Completed	NCT03169595
22	ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease	Recruiting	NCT02817997
23	Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease	Recruiting	NCT03300830
24	Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer	Recruiting	NCT00006518
25	Registry for Adults With Plasma Cell Disorders (PCD's)	Recruiting	NCT03717844
26	Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis	Active, not recruiting	NCT04742387
27	A Pilot Trial of Nelfinavir for the Lytic Activation and Treatment of Gammaherpesvirus-Related Tumors	Terminated	NCT02080416	Early Phase 1	Nelfinavir
28	The Castleman Disease Collaborative Network Biobank: A Collection of Biospecimens and Clinical Data to Facilitate Research	Withdrawn	NCT02871050

Search NIH Clinical Center for Castleman Disease

Inferred drug relations via UMLS ⁷⁰ / NDF-RT ⁵¹ :

siltuximab

Cochrane evidence based reviews: castleman disease

Sources

Genetic Tests for Castleman Disease

Sources

Anatomical Context for Castleman Disease

MalaCards organs/tissues related to Castleman Disease:

⁴⁰

Lymph Node, Bone, Bone Marrow, Endothelial, Skin, Kidney, Pancreas

Sources

Publications for Castleman Disease

Articles related to Castleman Disease:

(show top 50) (show all 1413)

#	Title	Authors	PMID	Year
1	A 5-year-old boy with unicentric Castleman disease affecting the mesentery: utility of serum IL-6 level and (18)F-FDG PET for diagnosis. ⁶¹ ⁵⁴	Toita N...Ariga T	19730402	2009
2	Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. ⁶¹ ⁵⁴	Nishimoto N...Kakehi T	18784373	2008
3	Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody. ⁵⁴ ⁶¹	Kanda J...Uchiyama T	17483056	2007
4	Bone marrow findings in multicentric Castleman disease in HIV-negative patients. ⁵⁴ ⁶¹	Kreft A...Kirkpatrick CJ	17325481	2007
5	Interleukin 6: from bench to bedside. ⁶¹ ⁵⁴	Nishimoto N...Kishimoto T	17075601	2006
6	[A case of HIV-1 and HHV-8-associated Castleman disease with a relapsing high fever and lymphoadenopathy]. ⁵⁴ ⁶¹	Minami R...Yamamoto M	16922487	2006
7	Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. ⁵⁴ ⁶¹	Wang J...Zhu XJ	16120143	2005
8	Intraventricular chordoid meningioma presenting with Castleman disease due to overproduction of interleukin-6. Case report. ⁶¹ ⁵⁴	Arima T...Yoshida J	15871519	2005
9	Acute myelogenous leukemia M5b developed during clinical remission of Castleman disease. ⁵⁴ ⁶¹	Tomonari A...Asano S	12731671	2003
10	High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. ⁵⁴ ⁶¹	Oksenhendler E...Meignin V	11895764	2002
11	The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. ⁶¹ ⁵⁴	An J...Rettig MB	11781250	2002
12	High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. ⁵⁴ ⁶¹	Oksenhendler E...Agbalika F	10979949	2000
13	[Advances in interleukin-6 therapy]. ⁵⁴ ⁶¹	Ogata A...Yoshizaki K	10340005	1999
14	Castleman disease in POEMS syndrome with elevated interleukin-6. ⁵⁴ ⁶¹	Emile C...Clauvel JP	8499003	1993
15	Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease. ⁶¹	Tosaki T...Yokoo T	33389670	2021
16	Autoimmune hypoglycemia expands the biological spectrum of HHV8+ multicentric Castleman disease. ⁶¹	Arnautou P...Boutboul D	33787862	2021
17	Response assessment and salvage indication for idiopathic multicentric Castleman disease. ⁶¹	Wang C	33215565	2021
18	Castleman disease and paraneoplastic pemphigus in a pregnant woman: A case report. ⁶¹	Cui B...Lin H	33787583	2021
19	A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease. ⁶¹	Butzmann A...Ohgami RS	33804823	2021
20	Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports. ⁶¹	Ferrero S...Ragaini S	33676575	2021
21	The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease. ⁶¹	Min GJ...Cho SG	32088937	2021
22	18F-FDG PET/CT imaging features of patients with multicentric Castleman disease. ⁶¹	Jiang Y...Cheng W	33741858	2021
23	A 10-year observational single-center study of retroperitoneal unicentric Castleman disease. ⁶¹	Wang W...Li H	33725899	2021
24	Castleman disease: A single-center case series. ⁶¹	Pribyl K...Harmon J	33631648	2021
25	Dysphagia and Dysphonia, a Pairing of Symptoms Caused by an Unusual Pair of Diseases: Castleman's Disease and Myasthenia Gravis. ⁶¹	Abdelmeguid A...Dewan K	32812444	2021
26	Emerging role of 18F-FDG PET/CT in Castleman disease: a review. ⁶¹	Koa B...Revheim ME	33709329	2021
27	Coexistence of disseminated Kaposi sarcoma and multicentric Castleman disease in an HIV-infected patient under viral suppression. ⁶¹	Lin IF...Lai CH	33555231	2021
28	Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. ⁶¹	Ramaswami R...Yarchoan R	33720337	2021
29	Evidence for altered host genetic factors in KSHV infection and KSHV-related disease development. ⁶¹	Blumenthal MJ...Schafer G	33043529	2021
30	HIV Lymphadenopathy: Differential Diagnosis and Important Imaging Features. ⁶¹	Glushko T...Simpson SA	33325733	2021
31	Systemic lupus erythematosus complicated with Castleman disease: a case-based review. ⁶¹	Demirkan FG...Aktay Ayaz N	32797278	2021
32	Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases. ⁶¹	Sun DP...Li JY	33544201	2021
33	Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab. ⁶¹	Furutera N...Shibata H	32715375	2021
34	Angiomatoid fibrous histiocytoma with Castleman disease: A case report. ⁶¹	Gu Y...Wu Z	32672859	2021
35	Unicentric Castleman Disease; the laparoscopic en bloc resection of a hypervascular Giant Lymph Node in the aortacaval zone. ⁶¹	Erdem B...Yilmaz G	33631872	2021
36	Pathologically confirmed oesophageal involvement in idiopathic multicentric Castleman disease mimicking early oesophageal cancer. ⁶¹	Tsuboi H...Sumida T	32885232	2021
37	Paraneoplastic pemphigus and fatal bronchiolitis obliterans associated with Castleman disease: Report of an autopsy case. ⁶¹	Sano Y...Uozaki H	33382501	2021
38	Author Correction: The value of multiparameter 18F-FDG PET/CT imaging in differentiating retroperitoneal paragangliomas from unicentric Castleman disease. ⁶¹	Jiang Y...Li F	33623136	2021
39	Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease. ⁶¹	Akiyama M...Takeuchi T	33249497	2021
40	Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease: reply. ⁶¹	Kawano M...Fajgenbaum DC	33253362	2021
41	Skin-associated lymphoid tissue could be a sign of systemic disease: reply from authors. ⁶¹	Kogame T...Kabashima K	33615442	2021
42	HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease. ⁶¹	Kawano M...Fajgenbaum DC	32772106	2021
43	UCD with MCD-like inflammatory state: surgical excision is highly effective. ⁶¹	Zhang MY...Li J	33570636	2021
44	Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. ⁶¹	van Rhee F...Wong RS	33128769	2021
45	Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions. ⁶¹	Fang X...Young KH	33215784	2021
46	Sequential change in serum VEGF levels in a case of tocilizumab-resistant TAFRO syndrome treated effectively with rituximab. ⁶¹	Wakiya R...Dobashi H	33269653	2021
47	Castleman Disease: An Unusual Cause of an Isolated Neck Mass. ⁶¹	Abuzayed B...Alawneh K	32796313	2021
48	Autoimmunity Due to Unicentric Castleman Disease Cured by Resection of a Hepatic Mass. ⁶¹	Im YR...Peters J	31609813	2021
49	Immune-mediated ataxia with cerebellar hemiatrophy and dystonia associated with Castleman disease. ⁶¹	Nuzhnyi E...Illarioshkin S	33338826	2021
50	Idiopathic multicentric Castleman disease with novel heterozygous Ile729Met mutation in exon 10 of familial Mediterranean fever gene. ⁶¹	Endo Y...Kawakami A	32830263	2021

Sources

Genes for Castleman Disease

Genes related to Castleman Disease (0 elite genes):

(show all 32)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	IL6	Interleukin 6	Protein Coding	25.22	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	18784373 9462253 17075601 (more) 19270642 10340005 10979949 12633573 8043430 9403701 8061104 8695726 7883866 10830746 2384605 9477139 2366383 2049864 1285994 1643291 19447768 7971857 7744000 8143505 8371004 19857312 17325481 17028666 15223659 12731671 9546694 17766835 15182131 11781250 10207568 1571900 17483056 17527041 17550864 17214583 15992152 10512402 9280606 9144766 8492420 20110057 20182422 19483409 19139722 19730402 17075187 16922487 16129906 14677035 12015752 10874763 15745091 12521189 11053081 20439324 20410258 18974624 15871519 15251133 11895764 10607684 15989626 9132332 8499003 1493429 1632458 1987276 10861641 10848977 10762119 10741750 9864581 9613678 8990099 7494511 7910717 19010373 8890706 8375854 20403026 10654928 10515899
2	IL6R	Interleukin 6 Receptor	Protein Coding	22.09	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	8890706 12633573
3	KRT15	Keratin 15	Protein Coding	18.99	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	11752170
4	CRP	C-Reactive Protein	Protein Coding	13.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	CR1	Complement C3b/C4b Receptor 1 (Knops Blood Group)	Protein Coding	13.25	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	IL10	Interleukin 10	Protein Coding	12.55	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	DSG3	Desmoglein 3	Protein Coding	11.95	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	16120143
8	IFNG	Interferon Gamma	Protein Coding	11.54	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	IL6ST	Interleukin 6 Cytokine Family Signal Transducer	Protein Coding	11.5	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	FSCN1	Fascin Actin-Bundling Protein 1	Protein Coding	11.44	Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	9556415
11	CXCL13	C-X-C Motif Chemokine Ligand 13	Protein Coding	11.34	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	11.21	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	CCL4	C-C Motif Chemokine Ligand 4	Protein Coding	11.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	MLANA	Melan-A	Protein Coding	10.39	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	10.15	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	FCER2	Fc Fragment Of IgE Receptor II	Protein Coding	10.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	H2AC18	H2A Clustered Histone 18	Protein Coding	9.83	DISEASES inferred ¹⁵ ¹⁵
18	MIR210	MicroRNA 210	RNA Gene	9.78	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	CR2	Complement C3d Receptor 2	Protein Coding	7.11	DISEASES inferred ¹⁵
20	SDC1	Syndecan 1	Protein Coding	6.66	DISEASES inferred ¹⁵
21	MYOM2	Myomesin 2	Protein Coding	6.64	DISEASES inferred ¹⁵
22	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	6.64	DISEASES inferred ¹⁵
23	CD4	CD4 Molecule	Protein Coding	6.6	DISEASES inferred ¹⁵
24	ACVRL1	Activin A Receptor Like Type 1	Protein Coding	6.59	GeneCards inferred via : Publications (show sections)
25	AR	Androgen Receptor	Protein Coding	6.59	GeneCards inferred via : Publications (show sections)
26	CD99	CD99 Molecule (Xg Blood Group)	Protein Coding	6.59	GeneCards inferred via : Publications (show sections)
27	DES	Desmin	Protein Coding	6.59	GeneCards inferred via : Publications (show sections)
28	F13A1	Coagulation Factor XIII A Chain	Protein Coding	6.59	GeneCards inferred via : Publications (show sections)
29	S100B	S100 Calcium Binding Protein B	Protein Coding	6.59	GeneCards inferred via : Publications (show sections)
30	PPL	Periplakin	Protein Coding	6.5	DISEASES inferred ¹⁵
31	TNFRSF8	TNF Receptor Superfamily Member 8	Protein Coding	6.4	DISEASES inferred ¹⁵
32	FAM120C	Family With Sequence Similarity 120C	Protein Coding	6.33	DISEASES inferred ¹⁵

Sources

Variations for Castleman Disease

Sources

Expression for Castleman Disease

Search GEO for disease gene expression data for Castleman Disease.

Sources

Pathways for Castleman Disease

Pathways related to Castleman Disease according to KEGG:

³⁶

#	Name	Kegg Source Accession
1	Cytokine-cytokine receptor interaction	hsa04060
2	JAK-STAT signaling pathway	hsa04630
3	Hematopoietic cell lineage	hsa04640

Pathways related to Castleman Disease according to GeneCards Suite gene sharing:

(show all 31)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁵ Show member pathways Immune System ⁶⁵ Neutrophil degranulation ⁶⁵	13.98	PDGFRB MTOR IL6ST IL6R IL6 IL10
2	PEDF Induced Signaling ⁶³ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶³ Cytokine-cytokine receptor interaction ³⁶ Endothelin-1 Signaling Pathway ⁶³ Glucocorticoid Receptor Signaling ⁶³ IL-6 Pathway ⁶³ MIF Mediated Glucocorticoid Regulation ⁶³ MIF Regulation of Innate Immune Cells ⁶³ NFAT Signaling and Lymphocyte Interactions ⁶³ PGC1Alpha Pathway ⁶³ RAR-Gamma-RXR-Alpha Degradation ⁶³ STAT3 Pathway ⁶³	13.59	PDGFRB MTOR IL6ST IL6R IL6 IL10
3	Cytokine Signaling in Immune system ⁶⁵ Show member pathways Signaling by Interleukins ⁶⁵	13.22	PDGFRB IL6ST IL6R IL6 IL10 IFNG
4	Pathways in cancer ³⁶	12.79	PDGFRB MTOR IL6ST IL6R IL6 IFNG
5	Th17 cell differentiation ³⁶ Show member pathways IL-22 Pathway ⁶³ Immune response IL-22 signaling pathway ²³ Inflammatory bowel disease ³⁶ Th1 and Th2 cell differentiation ³⁶	12.49	MTOR IL6ST IL6R IL6 IL10 IFNG
6	RANK Signaling in Osteoclasts ⁶³ Show member pathways Apoptosis and survival APRIL and BAFF signaling ²³ APRIL Pathway ⁶³ BAFF in B-Cell Signaling ⁶³ RANK Pathway ⁶³ RANKL/RANK (Receptor activator of NFKB (ligand)) Signaling Pathway ¹	12.37	MTOR IL10 FCER2 CR2 CCL4
7	IL-17 Family Signaling Pathways ⁶⁴ Show member pathways IL17 signaling pathway ¹ IL-17 signaling pathway ³⁶ Interleukin-17 signaling ⁶⁵ Mucin expression in CF via IL-6, IL-17 signaling pathways ²³	12.28	IL6ST IL6R IL6 IFNG
8	Translation Non-genomic (rapid) action of Androgen Receptor ²³ Show member pathways Basal cell carcinoma ³⁶ Transcription Androgen Receptor nuclear signaling ²³	12.26	MTOR IL6ST IL6R IL6
9	Tuberculosis ³⁶	12.18	IL6 IL10 IFNG CR1
10	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	12.13	MIR210 IL6R IL6 IL10
11	Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions ⁶⁴ Show member pathways Chemokine receptors bind chemokines ⁶⁵ Viral protein interaction with cytokine and cytokine receptor ³⁶	12.07	IL6ST IL6R IL6 IL10 CXCL13 CCL4
12	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁴	11.93	SDC1 IL6 IL10 IFNG
13	JAK-STAT signaling pathway ³⁶ Show member pathways B-Cell Development ⁶³ IL-7 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types ⁶⁴ Interleukin-19, 20, 22, 24 ⁶⁵ Jak/STAT Signaling Pathway ⁶⁴ Type III interferon signaling ¹	11.9	PDGFRB MTOR IL6ST IL6R IL6 IL10
14	HIF-1 signaling pathway ³⁶	11.87	MTOR IL6R IL6 IFNG
15	Interleukin-4 and 13 signaling ⁶⁵	11.86	IL6R IL6 IL10 FSCN1 FCER2
16	Senescence and Autophagy in Cancer ¹	11.79	MTOR IL6ST IL6R IL6 IFNG
17	Th17 Differentiation Pathway ⁶⁴ Show member pathways IL-21 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types ⁶⁴	11.78	IL6ST IL6R IL6 IFNG
18	IL-6 signaling pathway ¹ Show member pathways IL6-mediated signaling events ¹	11.75	IL6ST IL6R IL6 CRP
19	Hematopoietic cell lineage ³⁶	11.72	IL6R IL6 FCER2 CR2 CR1
20	Dendritic Cells Developmental Lineage Pathway ⁶⁴	11.7	IL6 IL10 IFNG
21	Th1 Differentiation Pathway ⁶⁴ Show member pathways IL27-mediated signaling events ¹	11.68	IL6ST IL6 IL10 IFNG
22	IL4-mediated signaling events ¹	11.61	MTOR IL10 FCER2
23	Interleukin-6 family signaling ⁶⁵ Show member pathways IL-6-type cytokine receptor ligand interactions ⁶⁵ Interleukin-6 signaling ⁶⁵	11.57	IL6ST IL6R IL6
24	RAF-independent MAPK1/3 activation ⁶⁵ Show member pathways MAPK1 (ERK2) activation ⁶⁵ MAPK3 (ERK1) activation ⁶⁵	11.42	IL6ST IL6R IL6
25	Interleukin-10 signaling ⁶⁵	11.42	IL6 IL10 FCER2 CCL4
26	IgA-Producing B Cells in the Intestine ⁶⁴	11.37	IL6 IL10 CXCL13 CR2 CR1
27	African trypanosomiasis ³⁶	11.35	IL6 IL10 IFNG
28	IL-15 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types ⁶⁴ Show member pathways IL-2 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types ⁶⁴	11.33	IL10 IFNG CCL4
29	Immune response_IL-6 signaling pathway ²³	11.29	IL6ST IL6R IL6
30	Cytokines and Inflammatory Response ¹	11.2	IL6 IL10 IFNG
31	Malaria ³⁶	10.72	SDC1 IL6 IL10 IFNG CR1

Sources

GO Terms for Castleman Disease

Cellular components related to Castleman Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular exosome	GO:0070062	9.97	SDC1 KRT15 IL6ST H2AC18 FSCN1 FCER2
2	extracellular space	GO:0005615	9.91	MIR210 IL6ST IL6R IL6 IL10 IFNG
3	extracellular region	GO:0005576	9.85	SDC1 IL6ST IL6R IL6 IL10 IFNG
4	receptor complex	GO:0043235	9.67	PDGFRB IL6ST IL6R CR2
5	ciliary neurotrophic factor receptor complex	GO:0070110	8.96	IL6ST IL6R
6	interleukin-6 receptor complex	GO:0005896	8.8	IL6ST IL6R IL6

Biological processes related to Castleman Disease according to GeneCards Suite gene sharing:

(show all 25)

#	Name	GO ID	Score	Top Affiliating Genes
1	inflammatory response	GO:0006954	9.97	SDC1 IL6 CXCL13 CRP CCL4
2	positive regulation of cell proliferation	GO:0008284	9.95	PDGFRB IL6ST IL6R IL6 IFNG CR1
3	immune response	GO:0006955	9.88	IL6 IL10 IFNG CXCL13 CR2 CCL4
4	regulation of actin cytoskeleton organization	GO:0032956	9.79	PDGFRB MTOR FSCN1
5	response to glucocorticoid	GO:0051384	9.77	SDC1 IL6 IL10
6	response to activity	GO:0014823	9.72	MTOR IL6 IL10
7	monocyte chemotaxis	GO:0002548	9.7	IL6R IL6 CCL4
8	positive regulation of chemokine production	GO:0032722	9.69	IL6R IL6 IFNG
9	acute-phase response	GO:0006953	9.67	IL6R IL6 CRP
10	positive regulation of MHC class II biosynthetic process	GO:0045348	9.62	IL10 IFNG
11	neutrophil mediated immunity	GO:0002446	9.62	IL6R IL6
12	negative regulation of lipid storage	GO:0010888	9.61	IL6 CRP
13	positive regulation of extracellular matrix disassembly	GO:0090091	9.59	IL6 FSCN1
14	T-helper 17 cell lineage commitment	GO:0072540	9.58	IL6R IL6
15	vascular endothelial growth factor production	GO:0010573	9.58	IL6R IL6
16	positive regulation of killing of cells of other organism	GO:0051712	9.56	IFNG FCER2
17	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.56	IL6ST IL6R IL6 IFNG
18	ciliary neurotrophic factor-mediated signaling pathway	GO:0070120	9.54	IL6ST IL6R
19	interleukin-6-mediated signaling pathway	GO:0070102	9.5	IL6ST IL6R IL6
20	positive regulation of ferrous iron import across plasma membrane	GO:1904440	9.46	MIR210 IFNG
21	positive regulation of osteoblast differentiation	GO:0045669	9.46	MIR210 IL6ST IL6R IL6
22	interleukin-11-mediated signaling pathway	GO:0038154	9.43	IL6ST IL6R
23	hepatic immune response	GO:0002384	9.37	IL6R IL6
24	positive regulation of smooth muscle cell proliferation	GO:0048661	9.26	PDGFRB MTOR IL6R IL6
25	cytokine-mediated signaling pathway	GO:0019221	9.23	SDC1 IL6ST IL6R IL6 IL10 FSCN1

Molecular functions related to Castleman Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	ciliary neurotrophic factor receptor activity	GO:0004897	9.4	IL6ST IL6R
2	interleukin-11 binding	GO:0019970	9.37	IL6ST IL6R
3	cytokine activity	GO:0005125	9.35	IL6 IL10 IFNG CXCL13 CCL4
4	interleukin-11 receptor activity	GO:0004921	9.32	IL6ST IL6R
5	interleukin-6 binding	GO:0019981	9.26	IL6ST IL6R
6	interleukin-6 receptor activity	GO:0004915	9.16	IL6ST IL6R
7	interleukin-6 receptor binding	GO:0005138	8.8	IL6ST IL6R IL6

Sources

Sources for Castleman Disease

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Apr-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia

Castleman Disease

Aliases & Classifications for Castleman Disease

MalaCards integrated aliases for Castleman Disease:

Classifications:

External Ids:

Summaries for Castleman Disease

Related Diseases for Castleman Disease

Diseases related to Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Castleman Disease:

Symptoms & Phenotypes for Castleman Disease

Human phenotypes related to Castleman Disease:

MGI Mouse Phenotypes related to Castleman Disease:

Drugs & Therapeutics for Castleman Disease

Drugs for Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Cochrane evidence based reviews: castleman disease

Genetic Tests for Castleman Disease

Anatomical Context for Castleman Disease

MalaCards organs/tissues related to Castleman Disease:

Publications for Castleman Disease

Articles related to Castleman Disease:

Genes for Castleman Disease

Genes related to Castleman Disease (0 elite genes):

Variations for Castleman Disease

Expression for Castleman Disease

Pathways for Castleman Disease

Pathways related to Castleman Disease according to KEGG:

Pathways related to Castleman Disease according to GeneCards Suite gene sharing:

GO Terms for Castleman Disease

Cellular components related to Castleman Disease according to GeneCards Suite gene sharing:

Biological processes related to Castleman Disease according to GeneCards Suite gene sharing:

Molecular functions related to Castleman Disease according to GeneCards Suite gene sharing:

Sources for Castleman Disease

Inferred drug relations via UMLS ⁷⁰ / NDF-RT ⁵¹ :